Nektar Therapeutics stock forecast
Want to see NKTR full AI Analyst Report?
Nektar Therapeutics (NKTR) Stock Forecast & Price Target
NKTR Analyst Ratings
NKTR Stock 12 Month Forecast
Average Price Target
$138.00▲(356.95% Upside)Detailed List of Analyst Forecasts
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Arthur He CFA | H.C. Wainwright | $185 | buy | 512.58%Upside | Reiterated | 11/16/26 | ||
| Edward Nash | Canaccord Genuity | $153→$149 | buy | 393.38%Upside | Reiterated | 11/16/26 | ||
| Oppenheimer | $140 | buy | 363.58%Upside | Reiterated | 11/13/26 | |||
| Yasmeen Rahimi | Piper Sandler | $192 | buy | 535.76%Upside | Reiterated | 11/13/26 | ||
| Martin Fan | Wedbush | $50→$40 | hold | 32.45%Upside | Reiterated | 11/13/26 | ||
| Will Soghikian | Leerink Partners | $130 | buy | 330.46%Upside | Reiterated | 11/13/26 | ||
| Alice Nettleton | UBS | $53 | hold | 75.50%Upside | Initiated | 10/11/26 | ||
| Julian Harrison | BTIG | $178 | buy | 489.40%Upside | Reiterated | 10/09/26 | ||
| Thomas Deal | Raymond James | ― | hold | ― | Initiated | 10/08/26 | ||
| Samantha Semenkow | Citi | $151 | buy | 400.00%Upside | Reiterated | 10/05/26 | ||
| B. Riley Securities | $150 | buy | 396.69%Upside | Reiterated | 10/02/26 | |||
| Andy Hsieh | William Blair | ― | buy | ― | Reiterated | 10/01/26 | ||
| Roger Song | Jefferies | $150 | buy | 396.69%Upside | Reiterated | 10/01/26 | ||
| Jessica Fye | J.P. Morgan | $65 | hold | 115.23%Upside | Initiated | 08/21/26 | ||
| Marc Frahm | TD Cowen | ― | buy | ― | Reiterated | 08/13/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Arthur He CFAH.C. Wainwright | BuyReiterated$185 | 11/16/26 | 512.58%Upside | ||
| Edward NashCanaccord Genuity | BuyReiterated$153→$149 | 11/16/26 | 393.38%Upside | ||
| BuyReiterated$140 | 11/13/26 | 363.58%Upside | |||
| Yasmeen RahimiPiper Sandler | BuyReiterated$192 | 11/13/26 | 535.76%Upside | ||
| Martin FanWedbush | HoldReiterated$50→$40 | 11/13/26 | 32.45%Upside | ||
| Will SoghikianLeerink Partners | BuyReiterated$130 | 11/13/26 | 330.46%Upside | ||
| Alice NettletonUBS | HoldInitiated$53 | 10/11/26 | 75.50%Upside | ||
| Julian HarrisonBTIG | BuyReiterated$178 | 10/09/26 | 489.40%Upside | ||
| Thomas DealRaymond James | HoldInitiated | 10/08/26 | ― | ||
| Samantha SemenkowCiti | BuyReiterated$151 | 10/05/26 | 400.00%Upside | ||
| BuyReiterated$150 | 10/02/26 | 396.69%Upside | |||
| Andy HsiehWilliam Blair | BuyReiterated | 10/01/26 | ― | ||
| Roger SongJefferies | BuyReiterated$150 | 10/01/26 | 396.69%Upside | ||
| Jessica FyeJ.P. Morgan | HoldInitiated$65 | 08/21/26 | 115.23%Upside | ||
| Marc FrahmTD Cowen | BuyReiterated | 08/13/26 | ― |
Best Analysts Covering Nektar Therapeutics
Copying Arthur He CFA's trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of +25.36% per trade.
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +140.24% per trade.
Copying Yasmeen Rahimi's trades and holding each position for 2 Years would result in 43.75% of your transactions generating a profit, with an average return of +33.65% per trade.
NKTR Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 9 | 11 | 15 | 18 | 16 |
| Buy | 2 | 2 | 2 | 3 | 1 |
| Hold | 1 | 2 | 3 | 5 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 12 | 15 | 20 | 26 | 21 |
In the current month, NKTR has received 17 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. NKTR average Analyst price target in the past 3 months is 138.00.
NKTR Financial Forecast
NKTR Earnings Forecast
Next quarter’s earnings estimate for NKTR is -$2.47 with a range of -$3.50 to -$1.70. The previous quarter’s EPS was -$1.63. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
NKTR Sales Forecast
Next quarter’s sales forecast for NKTR is $9.22M with a range of $7.60M to $12.00M. The previous quarter’s sales results were $9.39M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

